Both in Medical Distributors · as of 9 Nov · Methodology
No figures for 3 years: earnings were negative at one end of the window or there is not enough history.
Percentile among sector peers, by month. Rows marked ↓ rank lower values higher.
Share price: close of 9 Nov; other figures: latest month, Nov 2026.
| Metric | ENTERO | MONOPHARMA |
|---|---|---|
| Size and price | ||
| Share Price | ₹2114.90 | ₹10.00 |
| Market Cap | ₹9216 cr | ₹18 cr |
| Revenue (TTM) | ₹7128 cr | ₹166 cr |
| Net Profit (TTM) | ₹168 cr | ₹1 cr |
| Valuation | ||
| P/E | 73.4x | 24.4x |
| P/B | 5.5x | 0.6x |
| P/S | 1.3x | 0.1x |
| Profitability | ||
| ROCE | 10.0% | 5.0% |
| ROE | 7.4% | 2.3% |
| Operating margin | 5.0% | — |
| Metric | ENTERO | MONOPHARMA |
|---|---|---|
| Balance sheet and cash | ||
| Debt / Equity | 0.4x | 1.8x |
| Interest cover | 4.3x | 1.7x |
| Cash conversion (3Y) | -0.1x | -1.7x |
| Cash Conversion Cycle | 74d | 196d |
| Ownership | ||
| Promoter holding | 52.4% | 56.7% |
| FII Holding | 4.4% | — |
| DII Holding | 15.5% | — |
| Share Count Change (1Y) | 0.0% | 0.0% |
| Price behaviour | ||
| 12M momentum | 99.0% | -54.6% |
| Drawdown from Peak | 0.0% | -85.7% |
| Volatility (1Y) | 42.4% | — |
Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment.